Veracyte Inc (NASDAQ:VCYT) Sellers Strengthened Their Shorts By 3.35% As Of Jun 27, 2018

June 27, 2018 - By Noel Courtney

Veracyte, Inc. (NASDAQ:VCYT) Corporate Logo

Big Money Sentiment decreased to 1.04 in 2018 Q1. It has change of 0.19, from 2017Q4’s 1.23. The ratio turned negative due to Veracyte, Inc. positioning: 4 sold and 24 reduced. 11 funds bought stakes and 18 increased stakes. Investors holded 21.45 million in 2017Q4 but now own 20.91 million shares or 2.49% less.
Blair William And Il invested in 21,850 shs. Venbio Select Advisor Lc reported 119,680 shs. Perkins Capital Mgmt, a Minnesota-based fund reported 19,380 shs. Tower Research Cap Lc (Trc) owns 4,942 shs. New York-based Millennium Mgmt Limited Liability has invested 0.01% in Veracyte, Inc. (NASDAQ:VCYT). Renaissance Technology Limited Co has 512,800 shs for 0% of their capital. Bridgeway Management invested 0.02% of its capital in Veracyte, Inc. (NASDAQ:VCYT). Zebra Capital Mngmt Lc accumulated 10,184 shs. Georgia-based Invesco has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Geode Management Limited Liability Com owns 155,288 shs for 0% of their capital. Manufacturers Life Ins The invested in 0% or 22,338 shs. Voya Limited Liability Com has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Board Of Trustees Of The Leland Stanford Junior University holds 0% or 12,500 shs. Goldman Sachs Grp Incorporated owns 40,058 shs or 0% of their US capital. 15,140 were accumulated by American Incorporated.

Veracyte, Inc. had 2 selling transactions and 0 insider purchases since June 12, 2018. This’s net activity of $276,513. The insider Hall Christopher M sold $180,464.

Veracyte Inc (NASDAQ:VCYT) had an increase of its shorted shares by 3.35%. It was published in June by FINRA the 836,700 shorted shares on VCYT. That’s 3.35% up from 809,600 shares. Former VCYT’s position will need 6 days to recover. It has 137,100 average volume. Veracyte Inc float short is 4.01%.

$9.29 was the last price.It’s downtrending since June 27, 2017 and is 6.02% down. VCYT underperformed the S&P 500 by 18.59%.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The firm is worth $319.07 million. The firm uses genomic technology to resolve diagnostic ambiguity.Last it reported negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Another two news for Veracyte, Inc. (NASDAQ:VCYT) were briefly announced by: Globenewswire.com on June 21, 2018 with title “New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business …”. The other Businesswire.com‘s article was titled “Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year” and announced on June 25, 2018.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.